Assessing VC funding in biotech

Go to the profile of Bruce Booth
Mar 08, 2019
0
0

Ever since Prospect Ventures handed back $150M of committed money to its limited partners, there has been plenty written on the lack of venture capital funding for the life sciences.

However, a deeper dive provides a better picture. Bruce Booth has done the diving, and he wrote a blog post about it.

His findings are similar to what we found when digging up research for a news analysis, scheduled for publication in the December issue of Nature Biotechnology. That piece looks at new funding models for today’s startups, and I’ll get it removed from behind our firewall and post a link on the blog next week, after embargo lifts. Until then, you can read Bruce Booth’s piece here.

Brady Huggett

Go to the profile of Bruce Booth

Bruce Booth

Chairman, DPhil, Partner

Focuses on novel biopharmaceutical products, therapeutic platforms, and innovative biomedical technologies. Currently chairman of AvroBio, miRagen Therapeutics, Nimbus Therapeutics, Rodin Therapeutics, and Quartet Medicine, and also serves on the boards of Lysosomal Therapeutics, Magenta Therapeutics, Unum Therapeutics, and Zafgen (NASDAQ:ZFGN)

No comments yet.